期刊
BIOSENSORS-BASEL
卷 12, 期 8, 页码 -出版社
MDPI
DOI: 10.3390/bios12080617
关键词
immunotherapy; clinical trial; dostarlimab; colon cancer; cancer therapy; drug delivery
资金
- Deanship of scientific research at Umm Al-Qura University [22UQU4290565DSR50]
- Indian Council of Medical Research (ICMR), New Delhi, India [35/10/2019-Nano/BMS, 5/13/8/2020/NCD-III]
Immunotherapy, especially the use of anti-PD-1 monoclonal antibody Dostarlimab, has shown promising results in various cancer treatments, with complete cure observed in colorectal cancer patients. This review emphasizes the mechanism of action of immunotherapy and discusses the ongoing clinical trials and combination therapies involving Dostarlimab to provide insights for future clinicians and researchers.
Immunotherapy is one of the four pillars of cancer treatment that has recently emerged as a beacon of hope for cancer patients. Certain immunotherapies, for example, immune checkpoint inhibitor therapy, monoclonal antibody therapy and chimeric antigen T-cell therapy have garnered extensive interest in response to their exceptional properties that activate the immune system to respond to cancer cells, inhibiting their progression. In the era of rapid development, dostarlimab, an anti-programmed cell death protein (PD-1) monoclonal antibody has mesmerized the medical profession by showing complete (100%) cure of patients with colorectal cancer. Not only this, the results obtained from clinical trials revealed no major side effects in any of the participants in the study. Dostarlimab has also shown promising results in endometrial cancer, ovarian cancer, melanoma, head and neck cancer, and breast cancer therapy. This review focuses upon the action of immunotherapy, extensively emphasizing the miraculous therapy to activate T-cells for cancer treatment. Based on this, we discuss major ongoing clinical trials and combination immunotherapies to enlighten future clinicians and researchers about the response of dostarlimab against various cancers.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据